重组欧文菌天冬酰胺酶(JZP458)治疗急性淋巴细胞白血病:2/3期AALL1931研究结果
AALL1931是一项与儿童肿瘤协作组合作的2/3期研究,评估JZP458(一种源自新型表达平台的重组欧文菌天冬酰胺酶)在对大肠杆菌来源天冬酰胺酶出现超敏反应或沉默失活的急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者中的疗效与安全性。每剂原计划培门冬酶由6剂肌注JZP458于周一/三/五替代,共评估三个方案:队列1a 25 mg/m2、1b 37.5 mg/m2、1c 25/25/50 mg/m2。共入组167例,队列1c在72小时和48小时维持NSAA≥0.1 IU/mL的比例分别为90%(44/49)和96%(47/49),3/4级治疗相关不良事件发生于86/167(51%)例。
要点
- 肌注JZP458 25/25/50 mg/m2周一/三/五方案在队列1c中72小时和48小时维持NSAA≥0.1 IU/mL的比例分别为90%和96%。
- 3/4级治疗相关不良事件发生于86/167(51%)例,导致停药的不良事件包括胰腺炎(6%)、过敏反应(5%)、丙氨酸氨基转移酶升高(1%)和高氨血症(1%)。
- 群体药代动力学模型模拟数据与观察数据吻合良好。
核心结论
- 肌注JZP458 25/25/50 mg/m2周一/三/五方案有效,安全性特征与其他天冬酰胺酶一致。
研究设计与样本
- AALL1931为与儿童肿瘤协作组合作的2/3期研究,入组对大肠杆菌来源天冬酰胺酶出现超敏反应或沉默失活的急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者167例。
- 每剂原计划培门冬酶由6剂肌注JZP458于周一/三/五替代,评估三个方案:队列1a 25 mg/m2(n=33)、队列1b 37.5 mg/m2(n=83)、队列1c 25/25/50 mg/m2(n=51)。
主要发现
- 72小时平均血清天冬酰胺酶活性:队列1a 0.16 IU/mL、队列1b 0.33 IU/mL、队列1c 0.47 IU/mL;48小时分别为0.45、0.88、0.66 IU/mL。
- 队列1c在72小时和48小时达到NSAA≥0.1 IU/mL的比例分别为90%(44/49)和96%(47/49)。
- 群体药代动力学模型模拟数据与观察数据吻合良好。
- 3/4级治疗相关不良事件发生于86/167(51%)例;导致停药的不良事件包括胰腺炎(6%)、过敏反应(5%)、丙氨酸氨基转移酶升高(1%)和高氨血症(1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AALL1931, a phase 2/3 study conducted in collaboration with the Children's Oncology Group, investigated the efficacy and safety of JZP458 (asparaginase erwinia chrysanthemi [recombinant]-rywn), a recombinant Erwinia asparaginase derived from a novel expression platform, in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma who developed hypersensitivity/silent inactivation to Escherichia coli-derived asparaginases. Each dose of a pegylated E coli-derived asparaginase remaining in patients' treatment plan was substituted by 6 doses of intramuscular (IM) JZP458 on Monday/Wednesday/Friday (MWF). Three regimens were evaluated: cohort 1a, 25 mg/m2 MWF; cohort 1b, 37.5 mg/m2 MWF; and cohort 1c, 25/25/50 mg/m2 MWF. Efficacy was evaluated by the proportion of patients maintaining adequate nadir serum asparaginase activity (NSAA ≥0.1 IU/mL) at 72 hours and at 48 hours during the first treatment course. A total of 167 patients were enrolled: cohort 1a (n = 33), cohort 1b (n = 83), and cohort 1c (n = 51). Mean serum asparaginase activity levels (IU/mL) at 72 hours were cohort 1a, 0.16, cohort 1b, 0.33, and cohort 1c, 0.47, and at 48 hours were 0.45, 0.88, and 0.66, respectively. The proportion of patients achieving NSAA ≥0.1 IU/mL at 72 and 48 hours in cohort 1c was 90% (44/49) and 96% (47/49), respectively. Simulated data from a population pharmacokinetic model matched the observed data well. Grade 3/4 treatment-related adverse events occurred in 86 of 167 (51%) patients; those leading to discontinuation included pancreatitis (6%), allergic reactions (5%), increased alanine aminotransferase (1%), and hyperammonemia (1%). Results demonstrate that IM JZP458 at 25/25/50 mg/m2 MWF is efficacious and has a safety profile consistent with other asparaginases. This trial was registered at www.clinicaltrials.gov as #NCT04145531.
引用
- Maese L, Loh ML, Choi MR, et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023. PMID: 36108304. doi:10.1182/blood.2022016923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。